JPM19
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...
Moderna appoints Piyali Mukherjee as Head of Medical Affairs, Europe and Middle East
Mukherjee has previously held senior leadership roles at Moderna and GSK
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
More than 600,000 people in the US were hospitalised due to flu-related illness last year
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
The vaccine is already approved in the US for use in adults aged 60 years and older
Medscape Education Global to Join Biotechs at Swiss Biotech Day
The Medscape Education Global team is excited to announce its participation in Swiss Biotech Day, taking place in Basel from May 5-6. This marks our inaugural attendance at this event,...
Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults
RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older